Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.60 |
| ▸ | CTSB | P07858 | 5/20 | 0.60 |
| ▸ | CTSK | P43235 | 10/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 3/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.51 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27497095 | 1.00 | CTSL (0.60) | CTSLCTSBCTSKCYP3A4CTSS | |
| SCHEMBL7162081 | 0.99 | CTSL (0.59) | CTSLCTSBCTSKCYP3A4CTSS | |
| Lithium SCHEMBL7162098 | 0.99 | CTSL (0.59) | CTSLCTSBCTSKCYP3A4CTSS | |
| SCHEMBL27557439 | 0.91 | CTSL (0.55) | CTSLCTSBCTSKCYP3A4CTSS | |
| SCHEMBL7375883 | 0.90 | CTSL (0.58) | CTSLCTSBCTSKCYP3A4CTSS | |
| Lithium Ion SCHEMBL7162088 | 0.88 | CTSL (0.56) | CTSLCTSBCTSKCYP3A4CTSS | |
| SCHEMBL222158 | 0.86 | CTSK (0.76) | CTSLCTSBCTSKCTSSCAPN1 | |
| SCHEMBL1823902 | 0.86 | CTSK (0.76) | CTSLCTSBCTSKCTSSCAPN1 | |
| SCHEMBL2366985 | 0.86 | CTSK (0.76) | CTSLCTSBCTSKCTSSCAPN1 | |
| SCHEMBL6183168 | 0.86 | CTSL (0.78) | CTSLCTSBCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1171870-C | Cysteine protease inhibitors | ʷ��˿�������ȳ�ķ����˾ | 2004-10-20 | — | — | CN | disclosed |
| US-20040180927-A1 | Inhibitors of cysteine protease | SMITHKLINE BEECHAM CORPORATION | 2004-09-16 | — | — | US | disclosed |
| EP-0936912-B1 | INHIBITORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORP (US) | 2004-02-11 | — | — | EP | disclosed |
| US-6586466-B2 | Enzyme inhibitor for use in the treatment of bone, oral, arthritic, paget's and hypercalcemic diseases | SMITHKLINE BEECHAM CORPORATION | 2003-07-01 | — | — | US | disclosed |
| US-6562842-B2 | Osteoporosis, oral diseases | SMITHKLINE BEECHAM CORPORATION | 2003-05-13 | — | — | US | disclosed |
| EP-1019046-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020173469-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-11-21 | — | — | US | disclosed |
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | THOMPSON SCOTT KEVIN (US) | 2002-10-24 | — | — | US | disclosed |
| US-20020128476-A1 | Inhibitors of cysteine protease | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | disclosed |
| US-20020077455-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-06-20 | — | — | US | disclosed |
| EP-1068304-A1 | TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY | SMITHKLINE BEECHAM CORPORATION (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-1019046-A1 | PROTEASE INHIBITORS | Smithkline Beecham (US) | 2000-07-19 | — | — | EP | disclosed |
| US-6057362-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| US-5998470-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1999053039-A1 | TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-21 | — | — | WO | disclosed |
| CN-1232399-A | Cysteine protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 1999-10-20 | — | — | CN | disclosed |
| EP-0934291-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0934291-A4 | — | SMITHKLINE BEECHAM CORP (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998048799-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1997016433-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180927-A1 | Inhibitors of cysteine protease | CTSK, CTSZ, CTSS | CTSL 7/4885CTSB 5/4885CTSK 1/4885 |
| US-20020128476-A1 | Inhibitors of cysteine protease | CTRC, RCE1, CTRL | CTSL 8/4885CTSB 60/4885CTSK 100/4885 |
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | PEPD, PREP, CPN1 | CTSL 22/4885CTSB 35/4885CTSK 64/4885 |
| US-20020173469-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | CTSL 14/4885CTSB 4/4885CTSK 1/4885 |
| US-20020077455-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | CTSL 14/4885CTSB 4/4885CTSK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.